# Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

> **NCT01559129** · PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 23 (actual)

## Conditions studied

- Scleroderma, Systemic
- Sclerosis, Systemic
- Systemic Scleroderma
- Systemic Sclerosis
- Interstitial Lung Disease

## Interventions

- **DRUG:** Pomalidomide (CC-4047)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01559129
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08-09
- **Primary completion:** 2016-11-03
- **Final completion:** 2016-11-03
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Enrollment was stopped early (see limitations and caveats section).
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01559129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01559129, "Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01559129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*